AstraZeneca posted $15.3 billion in first-quarter sales, led by Enhertu and Imfinzi, clearing the $14.7 billion analyst consensus and reinforcing CEO Pascal Soriot’s $80 billion 2030 revenue target.
Oncology and rare disease carried the quarter. Enhertu, the HER2-directed ADC co-developed with Daiichi Sankyo, delivered $831 million, up 34% on a constant exchange rate. Imfinzi hit $1.69 billion, up 30%. The rare disease unit combined for $2.4 billion, led by complement inhibitor Ultomiris at $1.27 billion.
Datroway, cleared by FDA last year, generated $43 million in Q1 alliance revenue: six times Guggenheim’s $7 million forecast. The bank last month forecast Datroway for blockbuster status by 2030 and raised its AstraZeneca 2030 forecast to $79.6 billion this month.
Three Phase 3 trials of tozorakimab in chronic obstructive pulmonary disease hit their primary endpoints, and efzimfotase alfa data in hypophosphatasia bolstered the rare disease slate.
There’s a catch. In a long-term extension study, tozorakimab didn’t significantly reduce severe exacerbation rates in former smokers, missing the primary endpoint. The company will present the data at a medical meeting before formal regulatory submission.
When Soriot set the target in 2024, analyst consensus sat at $66.8 billion. It caught up to $80 billion by December 2025. Guggenheim raised its forecast to $79.6 billion this month after the tozorakimab data. Still $400 million short.
— Sarah Chen